Loren Data's SAM Daily™

FBO DAILY ISSUE OF AUGUST 01, 2004 FBO #0979
SOLICITATION NOTICE

B -- BRCA1 and BRCA2 Gene Sequencing

Notice Date

7/30/2004
 

Notice Type

Solicitation Notice
 

NAICS

541990 — All Other Professional, Scientific, and Technical Services
 

Contracting Office

Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
 

ZIP Code

20852
 

Solicitation Number

NCI-40116-NG
 

Response Due

8/9/2004
 

Archive Date

8/24/2004
 

Point of Contact

Malinda Holdcraft, Purchasing Agent, Phone (301) 402-4509, Fax (301) 402-4513, - Caren Rasmussen, Lead Contract Specialist, Phone (301) 402-4509, Fax (301) 402-4513,
 

E-Mail Address

holdcram@exchange.nih.gov, cr214i@nih.gov
 

Description

The National Cancer Institute (NCI) Center for Cancer Research (CCR), Laboratory of Populations Genetics (LPG), plans to procure BRCA1/BRCA2 GENE SEQUENCING services with Myriad Genetic Laboratories, Inc., 320 Wakara Way, Salt Lake City, Utah 84108. The supplies and services herein are commercial as defined in FAR Part 12, and this acquisition is being made in accordance with the test program for using simplified procedures for certain commercial items as authorized in FAR Part 13. The North American Industry Classification System code is 541990 and the business size standard is $6M. The Laboratory of Population Genetics (LPG), Center for Cancer Research (CCR), is involved in numerous studies aimed at elucidating the genetic epidemiology of breast and ovarian cancer. These include collaborative studies with the Clinical Genetics Branch (CGB) of the Division of Cancer Epidemiology and Genetics (DCEG) and a study of the genetic epidemiology of familial breast cancer in Jordan that the LPG is leading. The LPG has a need to obtain complete sequencing of the two major breast/ovarian cancer susceptibility genes known as BRCA1 and BRCA2 as part of these research projects. Additionally, the LPG has a need for molecular testing for the presence of large deletions in the BRCA genes, which have been recently recognized as important contributors to hereditary breast/ovarian cancer susceptibility. The samples are from individuals with breast cancer or ovarian cancer or their family members. The current acquisition represents work to be done for the Government by Myriad Genetics, under a Memorandum of Understanding initially executed between the Provider and the National Cancer Institute in November 1999 and extended thereafter. The purpose of this MOU is to facilitate performance of these complex assays in support of NCI-sponsored clinical cancer genetics research. Myriad Genetic Laboratories, Inc. is the only source known to the NCI that can provide the above service. It is essential to the ongoing scientific integrity and validity of the research studies being supported to obtain future data in a manner which will permit reliable comparison with assay results already obtained. In order to insure comparability of subsequent assay results with those already performed, this procurement is proposed as a sole source acquisition. Failure to do so could invalidate the cornerstone of these important research projects, i.e., the accurate, timely and reliable classification of study participants with regard to their BRCA1/2 germline mutation status. Myriad Genetics owns the patents on both the BRCA1 and the BRCA2 genes, and thus is the only commercial vendor available to perform the required work. This is not a request for competitive quotations. However, if any interested party believes it can provide the above supplies, it may submit a statement of capabilities. All information furnished shall be in writing and must contain sufficient detail to allow NCI to determine if it can meet the above minimum specifications described herein. Capability statements must be received in the Contracting Office by 1:00 PM EST on August 9, 2004. If you have questions, please contact Malinda Holdcraft, Purchasing Agent via electronic mail at holdcram@excange.nih.gov or by fax at (301) 402-4513. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received shall be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. Solicitation number NCI-40116-NG must be stated on all correspondence.
 

Place of Performance

Address: Bethesda, MD

Zip Code: 20892

Country: USA
 

Record

SN00633716-W 20040801/040730211913 (fbodaily.com)
 

Source

FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |